



INVESTMENT PROPOSAL

Subject	Immune System Health
Summary	The project is aimed to identify a novel therapy to treat viral diseases that both suppress viruses and improve immune function
Description	<p>In case of chronic infections (when the pathogen is not cleared) or even when the virus has been totally suppressed by pharmacological actions (as it is often the case when treating AIDS patients) the immune system remains hyperactivated. This uncontrolled immune system hyperactivation ultimately results in immune exhaustion, accelerated aging, cardiovascular and other organ diseases.</p> <p>The target of the project is to develop new therapies that, besides reducing the amount of viruses in an infected individual's bloodstream, return immune system activation to normal levels. Even if the initial project efforts are focused on HIV/AIDS, the therapeutic approach can be expanded to treat other chronic and life-threatening viral infections.</p>
Team	The founder, an MD with 20 years of experience in Biotech management in Europe and USA, leads a team that combines scientific, business, legal and technology expertise (from Big Pharma and Small Biotech)
IPR	Molecules are patent protected
Development stage	<p>The approach to treat viral and chronic diseases has been validated, establishing a human Proof-of-Concept, using a two-drug compound.</p> <p>With "<i>in vitro</i>" and "<i>in vivo</i>" analysis, based on proprietary screening methods, single-molecule candidates have been identified.</p>
Development program	<p>The research activity, mainly carried out in Italy, shall be focused on setting a non-human primate Proof-of-Concept and on completing the Pre-Clinical phase for a new drug application and the Phase 1 clinical study.</p> <p>Investigation on possible application of the novel method on one additional viral disease (e.g. hepatitis) will also be performed, in order to significantly improve the value proposition towards Big Pharmas.</p> <p>The target is to achieve an M&A in 2015, after Phase 1 clinical study.</p>
Market	Beside HIV/AIDS, the therapeutic approach based on the dual-action mechanism can address diseases related to other viruses, chronic infections, cardiovascular disease and ageing, providing an improvement in survival and quality of life.
National / Global	The project addresses the global market
Investment characteristics	The proposed investment is covering a Round B (totaling 5,2 MEuros, large part of which has already been granted by a government contract). The required, remaining investment is equal to 1.35 MEuro in 3 years. The foreseen exit strategy is an M&A deal with a Big Pharma by 2015, with an envisaged 10-fold ROI for investors.

For more information: businessplan@officineinnovazione.it

